The rate the fibroblasts produce tropocollagen is proportional to these stimuli. Diseases, injuries and changes in the level of mechanical load may induce remodeling. An example of this phenomenon is the thickening of farmers hands. The remodeling of connective tissues is well known in bones by the Wolffs law (bone remodeling). Mechanobiology is the science that study the relation between stress and growth at cellular level.Growth and remodeling have a major role in the cause of some common soft tissue diseases, like arterial stenosis and aneurisms and any soft tissue fibrosis. Other instance of tissue remodeling is the thickening of the cardiac muscle in response to the growth of blood pressure detected by the arterial wall. Imaging techniques
There are certain issues that have to be kept in mind when choosing an imaging technique for visualizing soft tissue extracellular matrix (ECM) components. The accuracy of the image analysis relies on the properties and the quality of the raw data and, therefore, the choice of the imaging technique must be based upon issues such as:

Having an optimal resolution for the components of interest;
Achieving high contrast of those components;
Keeping the artifact count low;
Having the option of volume data acquisition;
Keeping the data volume low;
Establishing an easy and reproducible setup for tissue analysis.The collagen fibers are approximately 1-2 μm thick. Thus, the resolution of the imaging technique needs to be approximately 0.5 μm. Some techniques allow the direct acquisition of volume data while other need the slicing of the specimen.
EANM guidelines, endorsed by the SNMMI, suggest a variety of regimes in clinical use, for both children and adults.Product labeling for diagnostic 131I iobenguane recommends giving potassium iodide one day before injection and continuing 5 to 7 days following. 131I iobenguane used for therapeutic purposes requires a different pre-medication duration, beginning 24–48 hours before iobenguane injection and continuing 10–15 days after injection. Clinical trials
Iobenguane I 131 for cancers
Iobenguane I 131, marketed under the trade name Azedra, has had a clinical trial as a treatment for malignant, recurrent or unresectable pheochromocytoma and paraganglioma, and the FDA approved it on July 30, 2018. The drug is developed by Progenics Pharmaceuticals. References
External links
"Iobenguane". Drug Information Portal. U.S. National Library of Medicine. "Iobenguane I 131". Drug Information Portal. U.S. National Library of Medicine. "Iobenguane I 123". Drug Information Portal. U.S. National Library of Medicine. "iobenguane I 131". NCI Drug Dictionary. "Iobenguane I 131". National Cancer Institute. 15 August 2018.